

tahir99

Includes **BONUS** cards —
recently approved
hepatitis C products

2016/2017

Top 300 Pharmacy Drug Cards

The best and easiest way to
learn essential information
about the top 300 drugs

Jill Kolesar • Lee Vermeulen

Mc
Graw
Hill
Education

LANGGE[®]

Additional Resources

To access the additional content, included only with the purchase of Top 300 Pharmacy Drug Cards:

To download the Q&A MP3 audio files to your mobile device, go to www.Top300DrugCards.com.

This page intentionally left blank

Top 300 Pharmacy Drug Cards—2016/2017

Jill M. Kolesar, PharmD, BCPS, FCCP

Professor, University of Wisconsin-Madison School of
Pharmacy

Director, Analytical Instrumentation Laboratory for
Pharmacokinetics, Pharmacodynamics and
Pharmacogenetics (3P)

University of Wisconsin Carbone Comprehensive Cancer
Center Madison, Wisconsin

Lee C. Vermeulen, RPh, MS, FCCP, FFIP


Clinical Professor, University of Wisconsin-Madison
School of Pharmacy

Director, Center for Clinical Knowledge Management, UW
Health

Madison, Wisconsin



New York Chicago San Francisco Athens London Madrid Mexico City
Milan New Delhi Singapore Sydney Toronto



Notice

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

Copyright © 2016 by McGraw-Hill Education. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher, with the exception that the program listings may be entered, stored, and executed in a computer system, but they may not be reproduced for publication.

ISBN: 978-0-07-184235-8

MHID: 0-07-184235-7

The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-184233-4, MHID: 0-07-184233-0.

eBook conversion by codeMantra
Version 1.0

All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps.

McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a representative, please visit the Contact Us page at www.mhprofessional.com.

TERMS OF USE


This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill Education's prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.

THE WORK IS PROVIDED "AS IS." MCGRAW-HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.


This page intentionally left blank

Contents


Contributors	xv	AMITRIPTYLINE	8
Introduction	xvii	AMLODIPINE	9
Acknowledgments	xix	AMOXICILLIN	10
Preface Card Summary	xxi	AMOXICILLIN/CLAVULANATE	11
Preface A: Anatomy of a Flash Card	xxiii	ANASTROZOLE	12
Preface B: Weight and Measure Equivalents	xxxiii	ARIPIRAZOLE	13
Preface C: General Content Related to All Oral Contraceptives	xxxv	ATAZANAVIR	14
Preface D: General Content Related to the Treatment of Hypertension	xxxix	ATENOLOL	15
Preface E: General Content Related to the Treatment of Hypercholesterolemia	xliv	ATOMOXETINE	16
Preface F: Guide to Combination Cardiovascular Products	xlix	ATORVASTATIN	17
Preface G: Guide to Combination Vaccines	liii	AZELASTINE	18
Preface H: Guide to Cytochrome P450 (CYP) and UGT1A1 Metabolism	lv	AZITHROMYCIN	19
Preface I: Guide to Transporters	lxi	BACLOFEN	20
Preface J: Drugs That Affect Cardiac Rhythm	lxiii	BENZAEPRIl	21
Preface K: Drugs Affected by Gastric pH	lxv	BENZONATATE	22
Preface L: Abbreviations	lxvii	BENZTROPINE	23
ACYCLOVIR	1	BIMATOPROST	24
ADAPALENE	2	BISOPROLOL	25
ALBENDAZOLE	3	BRIMONIDINE	26
ALBUTEROL	4	BUDESONIDE	27
ALENDRONATE	5	BUDESONIDE/FORMOTEROL	28
ALLOPURINOL	6	BUPRENORPHINE/NALOXONE	29
ALPRAZOLAM	7		




BUPROPION	30	CLONIDINE	53
BUSPIRONE	31	CLOPIDOGREL	54
CANDESARTAN	32	CLOTRIMAZOLE/BETAMETHASONE	55
CARBAMAZEPINE	33	CODEINE	56
CARBIDOPA/LEVODOPA	34	COLCHICINE	57
CARISOPRODOL	35	COLESEVELAM	58
CARVEDILOL	36	CONJUGATED ESTROGENS	59
CEFDINIR	37	CYANOCOBALAMIN	60
CEFUROXIME	38	CYCLOBENZAPRINE	61
CELECOXIB	39	CYCLOSPORINE OPHTHALMIC	62
CEPHALEXIN	40	DABIGATRAN	63
CETIRIZINE	41	DARBEPOETIN	64
CHLORHEXIDINE	42	DARIFENACIN	65
CHLORTHALIDONE	43	DESVENLAFAXINE	66
CIPROFLOXACIN ORAL	44	DEXAMETHASONE ORAL	67
CIPROFLOXACIN OTIC	45	DEXLANSOPRAZOLE	68
CITALOPRAM	46	DEXMETHYLPHENIDATE	69
CLARITHROMYCIN	47	DIAZEPAM	70
CLINDAMYCIN ORAL	48	DICLOFENAC	71
CLINDAMYCIN TOPICAL	49	DICYCLOMINE	72
CLOBAZAM	50	DIGOXIN	73
CLOBETASOL	51	DILTIAZEM	74
CLONAZEPAM	52	DIPHENOXYLATE/ ATROPINE	75




DIPHtheria Toxoid	76	Ezetimibe	100
Dipyridamole	77	Famotidine	101
Divalproex	78	Febuxostat	102
Donepezil	79	Felodipine	103
Doxazosin	80	Fenofibrate	104
Doxepin	81	Fentanyl Transdermal	105
Doxycycline	82	Fexofenadine	106
Duloxetine	83	Fidaxomicin	107
Dutasteride	84	Finasteride	108
Efavirenz	85	Fluconazole	109
Eletriptan	86	Fluocinonide Topical	110
Emtricitabine/Tenofovir	87	Fluoxetine	111
Enalapril	88	Fluticasone Nasal Inhaler	112
Enoxaparin	89	Fluticasone Oral Inhaler	113
Entecavir	90	Fluticasone/Salmeterol	114
Epinephrine	91	Folic Acid	115
Epoetin	92	Fosinopril	116
Escitalopram	93	Furosemide	117
Esomeprazole	94	Gabapentin	118
Estradiol Oral	95	Gatifloxacin Ophthalmic	119
Estradiol Transdermal Patch	96	Gemfibrozil	120
Eszopiclone	97	Glimepiride	121
Ethinyl Estradiol and Etonogestrel Ring	98	Glipizide	122
Exenatide	99	Haemophilus influenzae, Type B, Conjugate	123




HEPATITIS A VACCINE, INACTIVATED	124	KETOCONAZOLE TOPICAL	147
HEPATITIS B VACCINE, RECOMBINANT	125	LABETALOL	148
HUMAN PAPILLOMAVIRUS VACCINE	126	LACOSAMIDE	149
HYDRALAZINE	127	LAMOTRIGINE	150
HYDROCHLOROTHIAZIDE	128	LANSOPRAZOLE	151
HYDROCODONE	129	LATANOPROST	152
HYDROCORTISONE TOPICAL	130	LEVALBUTEROL	153
HYDROXYCHLOROQUINE	131	LEVETIRACETAM	154
HYDROXYZINE	132	LEVOCETIRIZINE	155
IBANDRONATE	133	LEVOFLOXACIN	156
IBUPROFEN	134	LEVOTHYROXINE	157
IMIQUIMOD	135	LIDOCAINE TOPICAL PATCH	158
INDOMETHACIN	136	LINAGLIPTIN	159
INFLUENZA VIRUS VACCINE, INACTIVATED	137	LIRAGLUTIDE	160
INFLUENZA VIRUS VACCINE, LIVE	138	LISDEXAMFETAMINE	161
INSULIN	139	LISINAPRIL	162
INSULIN ASPART	140	LITHIUM CARBONATE	163
INSULIN DETEMIR	141	LORAZEPAM	164
INSULIN GLARGINE	142	LOSARTAN	165
INSULIN LISPRO	143	LOTEPREDNOL	166
IPRATROPIUM/ALBUTEROL	144	LOVASTATIN	167
IRBESARTAN	145	LUBIPROSTONE	168
ISOSORBIDE MONONITRATE	146	MARAVIROC	169



MEASLES, MUMPS, RUBELLA VACCINE, LIVE	170	MUPIROCIN	194
MECLIZINE	171	NAPROXEN	195
MEDROXYPROGESTERONE	172	NEBIVOLOL	196
MELOXICAM	173	NIACIN	197
MEMANTINE	174	NIFEDIPINE	198
MENINGOCOCCAL VACCINE	175	NITAZOXANIDE	199
METAXALONE	176	NITROFURANTOIN	200
METFORMIN	177	NITROGLYCERIN	201
METHADONE	178	NORTRIPTYLINE	202
METHOCARBAMOL	179	NYSTATIN SYSTEMIC	203
METHOTREXATE	180	NYSTATIN TOPICAL	204
METHYLPHENIDATE	181	OLANZAPINE	205
METHYLPREDNISOLONE	182	OLMESARTAN	206
METOCLOPRAMIDE	183	OLOPATADINE	207
METOPROLOL	184	OMEGA-3-ACID ETHYL ESTERS	208
METRONIDAZOLE	185	OMEPRAZOLE	209
MINOCYCLINE	186	ONDANSETRON	210
MIRTAZAPINE	187	ORAL CONTRACEPTIVE—BIPHASIC	211
MODAFINIL	188	ORAL CONTRACEPTIVE—MONOPHASIC	212
MOMETASONE NASAL	189	ORAL CONTRACEPTIVE—TRIPHASIC	213
MONTELUKAST	190	OSELTAMIVIR	214
MORPHINE ER	191	OXCARBAZEPINE	215
MOXIFLOXACIN	192	OXYBUTYNIN	216
MOXIFLOXACIN OPHTHALMIC	193	OXYCODONE	217



PANTOPRAZOLE	218	PROGESTERONE	241
PAROXETINE	219	PROMETHAZINE	242
PENICILLIN	220	PROPRANOLOL	243
PENTOSAN	221	QUETIAPINE	244
PERTUSSIS VACCINE, ACELLULAR	222	QUINAPRIL	245
PHENAZOPYRIDINE	223	RABEPRAZOLE	246
PHENOBARBITAL	224	RALOXIFENE	247
PHENTERMINE	225	RALTEGRAVIR	248
PHENYTOIN	226	RAMIPRIL	249
PIOGLITAZONE	227	RANITIDINE	250
PNEUMOCOCCAL VACCINE	228	RANOLAZINE	251
POLIOVIRUS VACCINE, INACTIVATED	229	REPAGLINIDE	252
POLYETHYLENE GLYCOL	230	RISEDRONATE	253
POTASSIUM CHLORIDE	231	RISPERIDONE	254
POTASSIUM IODIDE	231	RIVAROXABAN	255
PRAMIPEXOLE	233	ROPINIROLE	256
PRASUGREL	234	ROSIGLITAZONE	257
PRAVASTATIN	235	ROSUVASTATIN	258
PREDNISOLONE ORAL	236	ROTAVIRUS VACCINE, LIVE	259
PREDNISON	237	SAXAGLIPTIN	260
PREGABALIN	238	SERTRALINE	261
PRENATAL VITAMIN	239	SILDENAFIL	262
PROCHLORPERAZINE	240	SIMVASTATIN	263



SITAGLIPTIN	264	TRAVOPROST	283
SOLIFENACIN	265	TRAZODONE	284
SPIRONOLACTONE	266	TRIAMCINOLONE NASAL	285
SUMATRIPTAN	267	TRIAMCINOLONE TOPICAL	286
TACROLIMUS	268	TRIAMTERENE/HYDROCHLOROTHIAZIDE	287
TADALAFIL	269	TRIMETHOPRIM (TMP)/SULFAMETHOXAZOLE (SMZ)	288
TAMSULOSIN	270	VALACYCLOVIR	289
TEMAZEPAM	271	VALSARTAN	290
TERAZOSIN	272	VARDENAFIL	291
TERBINAFINE	273	VARENICLINE	292
TESTOSTERONE	274	VARICELLA VACCINE, LIVE	293
TETANUS TOXOID	275	VENLAFAXINE	294
THYROID	276	VERAPAMIL	295
TIOTROPIUM	277	VILAZODONE	296
TIZANIDINE	278	WARFARIN	297
TOLTERODINE	279	ZIPRASIDONE	298
TOLVAPTAN	280	ZOLPIDEM	299
TOPIRAMATE	281	ZOSTER VACCINE, LIVE	300
TRAMADOL	282		

This page intentionally left blank

Contributors

Editors

Jill M. Kolesar, PharmD, BCPS, FCCP
Professor, University of Wisconsin-Madison School of Pharmacy
Director, Analytical Instrumentation Laboratory for
Pharmacokinetics, Pharmacodynamics and Pharmacogenetics (3P)
University of Wisconsin Carbone Comprehensive Cancer Center
Madison, Wisconsin

Lee C. Vermeulen, RPh, MS, FCCP, FFIP
Clinical Professor, University of Wisconsin-Madison
School of Pharmacy
Director, Center for Clinical Knowledge Management
UW Health
Madison, Wisconsin

Contributing Editor

Karen J. Kopacek, RPh
Associate Professor (CHS), Associate Dean for
Student Affairs
University of Wisconsin-Madison School of Pharmacy
Madison, Wisconsin

Author—Vaccine Content

Mary S. Hayney, PharmD, MPH, FCCP, BCPS
Professor of Pharmacy (CHS)
University of Wisconsin-Madison
School of Pharmacy
Madison, Wisconsin


Faculty Advisory Panel

Trisha N. Branan, PharmD, BCPS
Clinical Assistant Professor
University of Georgia College of Pharmacy
Critical Care Clinical Pharmacist
Athens Regional Medical Center
Athens, Georgia

Fred Doloresco, PharmD, MS
Clinical Assistant Professor
University at Buffalo
Consultant Pharmacist
Erie County Medical Center
Buffalo, New York

Rachel Eyler, PharmD, BCPS
Assistant Clinical Professor
University of Connecticut
Storrs, Connecticut

Alex N. Isaacs, PharmD, BCPS
Clinical Assistant Professor
Purdue University College of
Pharmacy
Clinical Pharmacist—Internal
Medicine
Eskenazi Health
Indianapolis, Indiana



Emily N. Israel, PharmD, BCPS
Clinical Assistant Professor
Purdue University College of
Pharmacy
Clinical Pharmacy Specialist
Riley Hospital for Children
Indianapolis, Indiana

Amanda Peters Johnson, PharmD
Clinical Instructor
UNC Eshelman School of
Pharmacy
Chapel Hill, North Carolina

Nicholas Messinger, PharmD,
BCPS, BCACP
Assistant Professor of Pharmacy
Practice and Administrative
Sciences
University of Cincinnati James
L. Winkle College of Pharmacy
Cincinnati, Ohio

Andrea L. Porter, PharmD
Assistant Professor
University of Wisconsin School of
Pharmacy
Clinical Pharmacy Specialist
William S. Middleton Memorial
Veterans Hospital
Madison, Wisconsin

Brian A. Potoski, PharmD, BCPS
(AQ-ID)
Associate Professor
University of Pittsburgh School of
Pharmacy
Associate Director, Antibiotic
Management Program
University of Pittsburgh Medical
Center, Presbyterian Hospital
Pittsburgh, Pennsylvania

Jennifer Pruskowski, PharmD, BCPS, CGP
Assistant Professor, Department of Pharmacy
and Therapeutics
University of Pittsburgh School of Pharmacy
Palliative Care Clinical Pharmacy Specialist
UPMC Palliative Supportive Institute
Pittsburgh, Pennsylvania

Stacey Schneider, PharmD
Associate Professor of Pharmacy Practice
Northeast Ohio Medical University
MTM Services Manager
Giant Eagle Pharmacy
Rootstown, Ohio

Sachin Shah, PharmD, BCOP, FCCP
Texas Tech University HSC—School Of
Pharmacy
Advanced Hematology/Oncology Clinical
Pharmacist
Dallas VA Medical Center
Dallas, Texas

Nicole Rockich Winston, MS, PharmD
Assistant Professor of Pharmacy Practice
Marshall University School of Pharmacy
Huntington, West Virginia


Introduction

The selection of the most commonly prescribed medications was based on a number of reports evaluating medication use based on the number of prescriptions filled in the United States and the cost of those prescriptions.¹⁻³ Most estimates rely on data from IMS Health, using data from their National Prescription Audit. In addition to these sources, additional information was drawn from a wide range of professional journals to select the most relevant medications to include in this set of cards. Information on medication safety was drawn from multiple sources, but relied on a number of documents maintained by the Institute for Safe Medication Practices (ISMP), which can be found at www.ismp.org. Photographs were taken by the editors at the University of Wisconsin Hospital and Clinics pharmacies, as well as at Target Pharmacy in Madison, Wisconsin. Products with generic versions available in the US market have a representative generic product pictured. Brand name products are generally pictured if a generic version is not yet available in the United States.

It should be noted that these cards include multiple agents in some drug classes, and the information on those cards is very similar. While redundancy is considered a flaw in textbooks and other educational material, repeating information in these crowded classes of drugs is essential for the successful use of flash cards as a learning tool.

1. Brooks M. Top 100 Selling Drugs of 2013. 2014, Jan 30. Medscape. Available at <http://www.medscape.com/viewarticle/820011#1>. Accessed November 29, 2014.
2. Barthalow M. Top drugs of 2013. *Drug Topics*. Available at <http://www.pharmacytimes.com/publications/issue/2014/July2014/Top-Drugs-of-2013>. Accessed November 29, 2014.
3. Schumock GT, Li EC, Suda KJ, Matusiak LM, Hunkler RJ, Vermeulen LC, Hoffman JM. National trends in prescription drug expenditures and projections for 2014. *Am J Health Syst Pharm*. 2014;71(6):482-499.


This page intentionally left blank



Acknowledgments

The Editors acknowledge the contributions of the pharmacists at the University of Wisconsin Hospital and Clinics, particularly Joe Cesarz, PharmD and Gloria Call, PharmD, as well as Charlie Lee, RPh from Target Pharmacy, for their assistance with the development of these cards. Pharmacy students Aleta Smithbauer, Nicolette Bonamase, and Marissa Cullen from Northeast Ohio Medical University also contributed.

This page intentionally left blank



Preface Card Summary

1. Preface A: Anatomy of a Flash Card
2. Preface B: Weight and Measure Equivalents
3. Preface C: General Content Related to All Oral Contraceptives
4. Preface D: General Content Related to the Treatment of Hypertension
5. Preface E: General Content Related to the Treatment of Hypercholesterolemia
6. Preface F: Guide to Combination Cardiovascular Products
7. Preface G: Guide to Combination Vaccines
8. Preface H: Guide to Cytochrome P450 (CYP) and UGT1A1 Metabolism
9. Preface I: Guide to Transporters
10. Preface J: Drugs That Affect Cardiac Rhythm
11. Preface K: Drugs Affected by Gastric pH
12. Preface L: Abbreviations

This page intentionally left blank

Preface A: Anatomy of a Flash Card

Medication Name

Both generic and common brand names are listed.

Class

Medications are grouped into classes (“families”) based on their chemical, pharmacological, or clinical properties. It is often useful to study medications on a class-by-class basis, identifying similarities and differences among members of each class.


Controlled Substance Schedule

Title 21 of the United States Code (USC) is the Controlled Substances Act of 1970. It regulates medications with potential for abuse. These Federal regulations are overseen by the Drug Enforcement Administration, but many States have enacted more strict regulations based on them. Medications are placed into schedules based on their clinical use and their risk of abuse and dependence. It is important to note that some States change the Federal scheduling of certain medications. Under Federal law, a State cannot place a medication in a lower schedule than where it is placed by the Federal government (eg, States cannot change a drug placed in Federal Schedule II to Schedule III, IV, or V), but States can and do place certain medications in higher schedules (eg, changing a drug placed in Federal Schedule V into Schedule II, III, or IV, or changing a drug which is not a controlled substance under Federal law into a controlled substance within that State).

- *Schedule I*: No medical use, high abuse, and dependence potential.
- *Schedule II*: Legitimate medical use, high abuse, and dependence potential.
- *Schedule III*: Legitimate medical use, abuse, and dependence potential somewhat less than Schedule II.
- *Schedule IV*: Legitimate medical use, abuse, and dependence potential less than Schedule III.
- *Schedule V*: Legitimate medical use, limited abuse, and dependence potential.

Dosage Forms

The most common dosage forms and strengths are listed. Other dosage forms may exist, and may be referenced in the Clinical Pearls section.



Common FDA Label Indication, Dosing, and Titration

The US Food and Drug Administration (FDA) approves medications for market, and also approves specific indications for use and the doses for those uses. Some medications are approved for only one indication, while others are approved for many indications. In most cases, all FDA-approved (“labeled”) indications are listed with their approved doses.

Off-Label Uses

While every medication must be approved by the FDA for at least one indication before it is marketed, FDA approval is not always sought for subsequent indications. Prescribers are legally entitled to prescribe medications for any indication they feel is appropriate and clinically justified. In most cases, prescribers limit their use of medications to indications for which evidence supports safety and efficacy, as demonstrated in published clinical trials. While these may not be FDA-approved indications, “off-label” use is common and often completely appropriate. Common off-label uses are included, along with dosing recommendations.

MOA (Mechanism of Action)


The MOA is a succinct summary of the pharmacological properties of each medication.

Drug Characteristics

Each card includes a table summarizing key drug parameters, as outlined below.

Dose Adjustments Hepatic

A Child-Pugh Score can be used to assess hepatic dysfunction. The score employs five clinical measures of liver disease. Each is scored 1-3, with 3 indicating the most severe derangement of that measure. Based on the number of points for each measure, liver disease can be classified into Child-Pugh class A, B, or C.




Measure	1 Point	2 Points	3 Points
Total bilirubin, mg/dL	<2	2-3	>3
Serum albumin, g/L	>35	28-35	<28
INR	<1.7	1.71-2.20	>2.20
Ascites	None	Mild	Severe
Hepatic encephalopathy	None	Grade I-II	Grade III-IV

Points	Class	One-Year Survival	Two-Year Survival	Liver Dysfunction
5-6	A	100%	85%	Mild
7-9	B	81%	57%	Moderate
10-15	C	45%	35%	Severe

Dose Adjustments Renal

Dose adjustments for some (but not all) of medications that are renally eliminated are necessary in patients with renal dysfunction and hepatically eliminated medications in patients with hepatic dysfunction. Dose adjustments are made by either lowering the dose or dosing less frequently (eg, reducing from tid to daily dosing). The degree of renal dysfunction usually determines the degree of the dose adjustment. Definitions of renal and hepatic dysfunction are often inconsistent, but the recommended dose adjustments included in these flash cards are drawn from product package inserts and other sources. Clinicians should always exercise caution when treating patients with liver and/or kidney disease, and monitor carefully for signs of toxicity, even if dose adjustments are made.



In general, CrCl is used to assess renal function and is calculated with the following equations:

Cockcroft and Gault Equation:

$$\text{CrCl (males)} = [(140 - \text{age}) \times \text{IBW}] / (\text{Scr} \times 72)$$

$$\text{CrCl (females)} = [(140 - \text{age}) \times \text{IBW}] / (\text{Scr} \times 72) \times (0.85)$$

Estimate Ideal Body Weight in (kg):

Males: IBW = 50 kg + 2.3 kg for each inch over 5 ft

Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 ft

Normal Renal Function: CrCl = 50 mL/min or greater

Moderate Renal Impairment: CrCl = 30-50 mL/min

Severe Renal Impairment: CrCl = 10-29 mL/min

Renal Failure: CrCl = 9 mL/min or less


Dialyzable

Medications may be removed by peritoneal or hemodialysis, requiring dose adjustments and/or redosing after dialysis to replace drug lost. Many references provide details regarding the dialyzability of drugs, and these cards provide basic adjustment recommendations.

Pregnancy Category

The FDA rates and categorizes medications based on the level of risk of fetal harm that medications pose when taken by pregnant women. While these categories are discrete, it is important to recognize that they are sometimes set on the basis of theoretical risks. Clinical decisions must be made individually, weighing the potential risk to both the pregnant woman and the fetus. The pregnancy category of each medication is provided.

- *Category A:* Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
- *Category B:* Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.



- *Category C*: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
- *Category D*: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
- *Category X*: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.


For several years, the FDA has considered changes to the pregnancy and lactation risk rating systems, and while the old systems remains in place at the time these cards are being edited, they may change before the next edition is published. Information about the change can be found at the FDA web site, and excellent information about this situation can be found in these two papers: Ramoz LL, Patel-Shori, NM. Recent changes in pregnancy and lactation labeling: Retirement of risk categories. *Pharmacotherapy* 2014;34(4):389-395, and Singh A, Hughes GJ, Mazzola, N. New changes in pregnancy and lactation labeling. *US Pharm.* 2014;39(10):40-43.

Lactation

As with pregnancy categories, relatively little evidence is available to guide clinical decision making regarding the use of medications in women who are breast-feeding. In most cases, the risks to the child must be weighed against the benefits to the breast-feeding mother. In general, this assessment is based on the risk that an individual medication will be expressed in breast milk, and the risk that such an expression would cause to the infant who subsequently ingests it. As noted above, the FDA is considering changes to the pregnancy and lactation systems used to describe risk. The articles cited can be reviewed for information about this pending change.

Contraindications

Some medications should never be used in certain circumstances or under certain conditions. These situations are known as contraindications and are usually related to common and very dangerous adverse effects that must be avoided by selecting alternative therapeutic options.



Absorption

Pharmacokinetic parameters related to oral bioavailability (F) and the impact of food on absorption are provided.

Distribution

Pharmacokinetic data on extent and nature of distribution, including volume of distribution (Vd) and the extent of protein binding, are provided.

Metabolism

Pharmacokinetic data on metabolic pathways, including cytochrome P450 pathway of elimination and whether a drug is an enzyme inducer or inhibitor, are provided.

Elimination

Pharmacokinetic data on extent of renal (or other) elimination, as well as elimination half-life, are provided.

Pharmacogenetics


Pharmacogenetic information is included if the drug has pharmacogenetic information in the drug label. Generally, information is provided when a patient's genetic composition can affect drug exposure and clinical response variability, risk for adverse events, genotype-specific dosing, or mechanism of drug action. A complete list of drugs with pharmacogenetic information can be found at the following web site: <http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm>.

Black Box Warnings

The FDA requires manufacturers to list certain significant safety-related concerns in boxed warnings in their approved product package inserts. These “black box warnings” contain critical information for the safe use of those medications. Key black box warning content is included on each card. Additional information on black box warnings can be found at the following web site: <https://blackboxrx.com/app/index>.

Medication Safety Issues

Each card includes a table summarizing key medication safety concerns, as outlined as follows.



Suffixes

Many products are available in multiple formulations, for example, in delayed-release dosage forms. These dosage forms are often distinguished through the use of suffixes appended to the name of a different formulation of that same product. It is essential to exercise caution to avoid errors caused by confusing one product with another by omitting or not recognizing the additional suffix. Products that are available in multiple formulations, distinguished by a suffix (or occasionally, a prefix), are noted in this field.

“Tall Man” Letters

Many medications are spelled similarly, leading to substitution errors during prescribing, dispensing, or administration. The use of “Tall Man” lettering—distinguishing one medication from a different, similarly named medication, by capitalizing specific portions of the medication name (either brand or generic name)—has been shown to help prevent substitution errors. Those products for which Tall Man lettering is recommended are noted in this field.

Do Not Crush

Many solid oral dosage formulations are developed to release their active ingredient slowly over time. Crushing those dosage forms (eg, to enable administration through a nasogastric tube, or to make easier to swallow by patients with swallowing disorders) may be particularly dangerous. The formulations of certain products that should not be crushed are noted in this field. Sublingual dosage forms are meant to be dissolved under the tongue and swallowing these dosage forms without allowing them to dissolve lowers the efficacy of the drug. Some taste really bad, and patients prefer to swallow them without allowing them to dissolve.

High Alert

The Institute for Safe Medication Practices (ISMP) maintains a list of medications that are often involved in medication errors, or that are associated with a heightened risk of causing significant patient harm when used in error. Specific care must be exercised when prescribing, dispensing, or administering these products. More information on this field can be found at the ISMP web site at www.ismp.org.

Confused Names

Many medications are confused with other medications based on similarities in the spelling or pronunciation of their names, resulting in substitution errors. Those products that may be confused with different “look-alike or sound-alike” products are noted in this field.